Jonathan Grinstein
North American Editor at Inside Precision Medicine
Scientist turned storyteller. North American Editor @inside_pm. for story leads: [email protected]
Articles
-
3 days ago |
insideprecisionmedicine.com | Jonathan Grinstein
With its many blades that can cut through cancer from all sides, a Swiss Army knife is a better strategy than a single, exact surgical tool. That vision drives Faeth Therapeutics, a biotechnology company integrating cutting-edge therapies with dietary interventions to rewrite the rules for treating complex cancers like endometrial and breast cancer.
-
1 week ago |
insideprecisionmedicine.com | Jonathan Grinstein
If you still think that “junk DNA” is junk or that long noncoding RNAs (lncRNAs) are just a bunch of superfluous genome nonsense, well, you’re in for a rude awakening. Clue #1: Big Pharma has made significant investments in this field, notably Eli Lilly in HAYA Therapeutics for up to $1 billion and Bayer in Dana-Farber spinout NextRNA for up to $547 million.
-
1 week ago |
insideprecisionmedicine.com | Jonathan Grinstein
By harnessing the metabolic power of a molecule more commonly recognized for its function in immune regulation, scientists from Fudan University Shanghai have discovered a new method to enhance chimeric antigen receptor (CAR)-T cells.
-
1 week ago |
insideprecisionmedicine.com | Jonathan Grinstein
Scientists have developed a system that uses low-frequency electromagnetic fields (EMFs) to control gene expression in living cells, advancing minimally invasive medical technology. EMPOWER (Electromagnetic Programming of Wireless Expression Regulation) uses genetically modified cells triggered by nanoparticles electromagnetically stimulated via a proprietary interface to wirelessly regulate gene expression and release therapeutic proteins like insulin.
-
1 week ago |
insideprecisionmedicine.com | Jonathan Grinstein
Tissue paper. Cobwebs. Butterfly wings. This is the level of skin fragility experienced by patients with recessive dystrophic epidermolysis bullosa (RDEB), a condition that causes continuous blistering, excruciating wounds, and scarring that can cover more than 30% of the body surface and even up to 80% in extreme instances. Those who are born with a mutation in the COL7A1 gene, which codes for Type VII collagen, experience a life of constant physical and mental agony.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 460
- Tweets
- 442
- DMs Open
- Yes
Discover how @AllofUsCEO Josh Denny, MD, is harnessing diverse biological data to advance understanding of health disparities, rare diseases, and common conditions in this Behind the Breakthroughs episode by @Inside_PM [@sagepub]. @NIH @AllofUsResearch https://t.co/tVz5nRVVPc
RT @mehrzadsamadi: 🎧 Catch Harry Clifford on "Behind The Breakthroughs: Carrying Medicine Into the Post-Moore’s Law Era" podcast. Chatting…
RT @russopartners: Join us for The State of Precision Medicine 2025 on March 5! At 2:30 p.m. ET, @Inside_PM’s @GrinsteinJ hosts a panel wit…